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Background: Good-quality artemisinin drugs are essential for malaria treatment, but increasing prevalence of poor-
quality artemisinin drugs in many endemic countries hinders effective management of malaria cases.
Methods: To develop a point-of-care assay for rapid identification of counterfeit and substandard artemisinin drugs
for resource-limited areas, we used specific monoclonal antibodies against artesunate and artemether, and
developed prototypes of lateral flow dipstick assays. In this pilot test, we evaluated the feasibility of these dipsticks
under different endemic settings and their performance in the hands of untrained personnel.
Results: The results showed that the dipstick tests can be successfully performed by different investigators with the
included instruction sheet. None of the artemether and artesunate drugs collected from public pharmacies in
different endemic countries failed the test.
Conclusion: It is possible that the simple dipstick assays, with future optimization of test conditions and sensitivity,
can be used as a qualitative and semi-quantitative assay for rapid screening of counterfeit artemisinin drugs in
endemic settings.
Keywords: Artemisinin-based combination therapies (ACTs), Dipstick, Malaria, AntibodyBackground
It is estimated that 10–30 % of the pharmaceuticals in the
world are of poor quality [1]. Generally, poor-quality drugs
are falsified (deliberately and fraudulently manufactured
and mislabeled), substandard (produced by manufacturers
authorized by regulatory authorities, but not able to meet
quality specifications), or degraded during transport and
storage. Low-income countries with a high malaria burden
are particular targets for falsified drugs. The high disease
burden in these countries and resultant wide use of drugs
make these areas lucrative locations for the counterfeit
drug business. Artemisinin-based combination therapies
(ACTs), as the recommended first-line treatments for* Correspondence: wbaomin@263.net; luc2@psu.edu
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played an important role in reducing the global malaria-
associated mortality and morbidity. Good-quality ACTs
are essential for delivering effective malaria case manage-
ment, but the increasing proportions of poor-quality (both
counterfeit and substandard) drugs in many endemic
countries are concerning [2, 3]. Counterfeit artemisinins
containing little or no active ingredient provide inadequate
treatment and can be life-threatening [4]. In Sub-Saharan
Africa, it has been estimated that a large number of deaths
of children under age 5 were associated with consumption
of poor-quality antimalarials [5]. Therefore, heightened
surveillance and regulatory efforts are urgently needed for
combating the entry and circulation of poor-quality anti-
malarial drugs.
Accurate determination of artemisinin contents in com-
mercial drugs requires sophisticated instrumentation and
expertise. In resource-limited settings, thin-layer chro-
matography (TLC) is the often-used method fordistributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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Fig. 1 a The assembled dipsticks for analysis of artesunate/
artemether-containing drugs. The disappearance of the test line
indicates that concentration of the tested drug is above the limit of
detection of the dipstick. b Description of the test results according
to the instruction sheet. Concentration at LOD (limit of detection)
shows the potential results of the tested drug when diluted to the
LOD based on the described drug content
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in the Minilab from Global Pharma Health Fund, is a sys-
tem recommended by the World Health Organization
(WHO) for the detection of fake drugs. This method,
however, is qualitative, cumbersome, and laborious, and it
requires trained personnel to implement. In response to
the counterfeit artesunate monotherapy tablets in South-
east Asia, a colorimetric method was developed for rapidly
assessing drug authenticity [6, 7]. This method uses the
Fast Red TR salt to produce a yellow color upon reaction
with artemisinin derivatives, but this test cannot be used
in ACTs containing a yellow-colored partner drug such as
lumefantrine and amodiaquine. Recently, a new colorimet-
ric method was developed, but it requires caustic acids in
the assay, which can be difficult to manage in remote en-
demic settings [8]. To address the current limitations of
point-of-care (POC) diagnoses of fake artemisinins, we de-
veloped a series of monoclonal antibodies (mAbs) that
showed different specificities to artemisinin derivatives
[9, 10] for potential use in immunoassays for artemisi-
nin quantitation. Given that workers in malaria-
endemic populations are very familiar with the rapid
diagnostic test (RDT) format for malaria diagnosis [11],
we chose to develop a lateral flow dipstick for POC
tests that would provide qualitative and semi-
quantitative detection of artemisinins in antimalarial
drugs [12]. A prototype dipstick was designed based on
one selected mAb that was found to have high avidity
and broad reactivity for artemisinins, with sensitivity as
low as 100–200 and 200–500 ng/ml for artesunate and
dihydroartemisinin, respectively [12]. Recently, we have
developed additional mAbs that are highly specific for
artemether and artesunate, respectively [10, 13], and we
have attempted to improve the dipsticks and make
them specific for each of the artemisinin derivatives
commonly found in ACT drugs. To further improve
these dipsticks and to determine how these dipstick
tests perform under field settings, we distributed some
of the tests to several International Centers of Excellence
for Malaria Research (ICEMRs) for pilot evaluations. Here,
we report the results from these field evaluations and
make recommendations for improvements of the tests.
Methods
Development of colloidal gold-based lateral-flow
dipsticks
We have developed a dipstick that can be used as a POC
test for artemisinin-, artesunate-, and dihydroartemisinin-
containing drugs using a mAb (3D82G7) that has consider-
able cross-reactivities to these three compounds [12]. To
differentiate artemisinin and its derivatives in different
ACT drugs, we developed a dipstick using a mAb
(3D82G6) that is specific for artesunate [13]. Recently,
based on a mAb (2G12E1) that is specific for artemether[10], we developed a dipstick specifically for detecting
artemether in ACT drugs (described elsewhere). Here, we
used mAb 2G12E1 and mAb 3D82G6 to prepare two types
of dipsticks that are specific for artemether and artesunate,
respectively. Preparation of colloidal gold-conjugated anti-
bodies and assembly of the dipsticks were performed as
described earlier [12]. The sensitivities of these batches of
dipsticks (indicator ranges) were determined using serially
diluted artemether and artesunate, respectively [12]. The
final dipsticks (Fig. 1a) were then sealed in a plastic case
with desiccant gel and, together with the instruction sheet,
sent to different laboratories for evaluation.
Field testing of the dipsticks
Different brands of artemether- and artesunate-
containing drugs (19 artemether-lumefantrine drugs, 4
artesunate injections, and 1 artesunate-pyrimethamine-
sulphadoxine drug) were purchased from local pharma-
cies in Colombia, India, Papua New Guinea (PNG), and
Zambia. None of the drugs had passed their expiration
dates at the time of test. All tests were conducted lo-
cally under field conditions following the instructions
on the instruction sheet. The instruction sheet included
with the dipsticks described the type of dipstick in-
cluded, the materials provided (dipstick and a dropper),
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ing the dipstick, and instructions for interpreting the
results, all of which are detailed below.
Sample extraction
Individual drug tablets were crushed in a piece of folded
paper to a fine powder, which was transferred to ≥95 %
alcohol to produce a content of 2 mg/ml based on
the labeled content of the commercial drug. For arte-
sunate injections, the drug powders were dissolved
similarly in ≥95 % alcohol.
Dilution
Using a dropper included in the assay, a drop of the
stock was transferred to a cup containing 1.25 ml of
water for artesunate or 12.5 ml for artemether, which
should give a theoretical concentration of the drug
of ~40 μg/ml artesunate or ~4 μg/ml of artemether.
These different dilution schemes were used given
that the two dipsticks had different indicator ranges.
Dipstick assay
After rinsing the dropper at least three times with water,
the dropper was used to add three drops (or 80 μl) of
the diluted drugs to the sample well of the dipstick. The
color of the control and/or test lines was to be visible in
5 min (not beyond 15 min).
Result interpretation
For a valid assay with the control line visible, if the test
line showed no color, the drug was to be considered
qualified (Fig. 1b). If the test line showed a dark or faint
color, it suggested that the drug might be fake or sub-
standard. We suggested that the drug needed to be
tested at a drug concentration ten times higher (ten
times less dilution) to confirm the finding.
Results
The two mAbs against artemether and artesunate were
highly specific for these two artemisinin derivatives, re-
spectively. They were used to develop highly sensitive,Water
Artemether-Lumefantrine
Fig. 2 Artemether/lumefantrine (20/120) samples tested in PNG showing t
and 5–8), Lumartem (4), Coartem (9 and 10), and Coatal (11). The order of
the artemether/lumefantrine drugs tested in PNGindirect competitive enzyme-linked immunosorbent as-
says for accurate determination of artemether and arte-
sunate concentrations [10]. Since dipstick assays are
used to measure high concentrations of drugs, we specif-
ically lowered the sensitivity of the assay to avoid mul-
tiple dilution steps. Using serially diluted standard drugs,
the indicator ranges of the artemether and artesunate
dipsticks were determined in the laboratory as 4–8 and
40–50 μg/ml, respectively.
Since the primary goal of this pilot field test was to in-
vestigate the performances of the dipsticks as POC devices
in endemic settings, we wanted to know the performances
of the dipsticks in the hands of different investigators
under field conditions. Given the simplicity of the dipstick
assay and the familiarity of most malaria-endemic popula-
tions with the RDT format, no specific training on the use
of the assay was offered. All investigators followed the in-
structions and successfully performed the dipstick assays
under field conditions. After initially dissolving the drug
powder in ≥95 % alcohol, the stock solutions were further
diluted using regular bottled water. Since the main
purpose was to test applicability of the dipsticks in re-
mote endemic settings, rather than to screen counter-
feit and substandard drugs, all drugs were purchased
from pharmacies in public clinics and hospitals. The test
results showed that all tested artemether/lumefantrine,
artesunate/pyrimethamine/sulphadoxine, and artesunate
injections contained the described amounts of active
pharmaceutical ingredients (Fig. 2, Table 1).
Additional evaluations using slight variations of the
protocol also were performed in different field sites. In
PNG, when initial drugs (artemether 20 mg/lumefan-
trine 120 mg) were dissolved in 10 ml of water as stock
solutions, diluted in water to ~2 μg/ml, and tested on
the artemether dipstick, the test line in the dipstick
showed a faint band compared to the complete
disappearance that occurred when the same drugs were
dissolved in alcohol per instruction. This result is con-
sistent with the poor solubility of artemether in water.
At the Colombian site (Buernaventura, Valle), investiga-
tors also applied the same CoArtem® 20/120 drugs on 20/120 (4 µg/ml)
hat all tested drugs passed the tests. Drugs tested include Artefan (1–3
the dipsticks shown here is the same as the order listed in Table 1 for
Table 1 Test results of ACT commercial drugs and artesunate injections by dipsticks in PNG, India, and Zambia
Drug namea Drug composition Area of procurement Result
Larinate-200 Kit Artesunate 200 mg pyrimethamine 25 mg sulphadoxine
500 mg
Agartala, Tripura, India Qualified
Lumether Forte DT Artemether 80 mg lumefantrine 480 mg Agartala, Tripura, India Qualified
Lumerax-80 Artemether 80 mg lumefantrine 480 mg Agartala, Tripura, India Qualified
Micromether-LF Artemether 80 mg lumefantrine 480 mg Tinsukia, Assam, India Qualified
Falcigo Artesunate 60 mg Dibrugarh, Assam, India Qualified
Rtsunate Artesunate 60 mg Dibrugarh, Assam, India Qualified
Artesun—60 mg vial for IM/IV Artesunate 60 mg Mugil Clinic, Madang, PNG Qualified
Artesun—60 mg vial for IM/IV Artesunate 60 mg Mugil Clinic, Madang, PNG Qualified
Artefan 20/120—packaged for 15–24 kg Artemether 20 mg lumefantrine 120 mg Elaita Clinic, Maprik, PNG Qualified
Artefan 20/120—packaged for 15–24 kg Artemether 20 mg lumefantrine 120 mg Elaita Clinic, Maprik, PNG Qualified
Artefan 20/120—packaged for >35 kg and adults Artemether 20 mg lumefantrine 120 mg Mugil Clinic, Madang, PNG Qualified
Lumartem—packaged for 5–15 kg Artemether 20 mg lumefantrine 120 mg Mugil Clinic, Madang, PNG Qualified
Artefan 20/120—packaged for 15–24 kg Artemether 20 mg lumefantrine 120 mg Mugil Clinic, Madang, PNG Qualified
Artefan 20/120—packaged for >35 kg and adults Artemether 20 mg lumefantrine 120 mg Maprik Hospital, PNG Qualified
Artefan 20/120—packaged for 25–34 kg Artemether 20 mg lumefantrine 120 mg Elaita Clinic, Maprik, PNG Qualified
Artefan 20/120—packaged for 15–24 kg Artemether 20 mg lumefantrine 120 mg Elaita Clinic, Maprik, PNG Qualified
Coartem 20/120—packaged for 15–24 kg Artemether 20 mg lumefantrine 120 mg Elaita Clinic, Maprik, PNG Qualified
Coartem 20/120—packaged for 15–24 kg Artemether 20 mg lumefantrine 120 mg PNGIMR Maprik, PNG Qualified
Coatal 20/120—packaged with dosage chart Artemether 20 mg lumefantrine 120 mg Wewak Pharmacy, PNG Qualified
Coartem 20/120(5 different lots) Artemether 20 mg lumefantrine 120 mg Zambia Qualified
aEach sample was analyzed in triplicate
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dipstick produced a result showing the drug was quali-
fied, whereas the same drug failed the artesunate dip-
stick. This is consistent with the high specificities and
low cross-reactivities of the two mAbs used to develop
the two dipsticks. At the Indian site (Assam State), in-
vestigators also tried six dilutions of artesunate with final
concentrations of 2, 4, 8, 10, 20, and 40 μg/ml on the
artesunate dipsticks. The result showed that the test line
was clearly visible at 2 μg/ml, faint at 4 μg/ml, and com-
pletely invisible at 8 μg/ml, which agreed well with the
sensitivity of the dipstick determined under laboratory
conditions.
Discussion
We have demonstrated that the mAb-based dipstick as-
says for detecting artemisinin and its derivatives in
ACT drugs performed well in field conditions without
the requirement for technical training of the test per-
formers. Compared to most of the currently available
assays for quality control of artemisinin-containing
drugs at field sites, this method offers several advan-
tages. First, it has a very simple sample preparation
step, which involves crushing drug tablets, dissolving
the drug powder in ≥95 % alcohol, and further diluting
the solution with water. Second, the protocol is fastand takes about 10 min from the beginning of the assay
to the final reading of the result. Third, we have found
that ≥95 % alcohol for the initial preparation of the
stock solution performed sufficiently well for field-
testing purposes, thus avoiding the need for flammable
organic solvents, such as acetonitrile. Fourth, as shown
in the lab tests, the partner drugs in the ACTs do not
interfere with the assays, though more vigorous tests
are needed on other ACTs such as artesunate/meflo-
quine and artesunate/amodiaquine. Finally, the high
specificities of these two mAbs for artemether and arte-
sunate with only 2–4 % cross-reactivity to artemisinin
give the dipsticks another advantage for identifying
ACTs containing these ingredients only [10, 13]. Poten-
tially, these dipsticks could identify counterfeit drugs
containing the easily obtainable natural product artemi-
sinin, which may thwart some chemical tests. These
features make the dipstick assay a truly suitable POC
device for preliminary quality screening of artemisinin
drugs in resource-limiting countries.
In recognition of the challenges for detecting counter-
feit antimalarials in developing countries, Green et al.
proposed a three-tiered drug evaluation strategy [8]. We
envision that the dipstick device could be a nice fit as a
Tier III assay for the purpose of screening to identify
suspicious counterfeit drugs since the amount of the
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Dipsticks can easily be carried to highly remote areas
and used on site, while the results can be sent back to
regulatory agencies as digital cell phone pictures. Suspi-
cious drugs can then be sent to central labs for accurate
testing. Furthermore, each batch of dipsticks has a
roughly defined sensitivity range, thus allowing the per-
formers to obtain an estimated range of the drug con-
tent. Moreover, by performing different dilutions of the
sample, the drug content can be more narrowly defined.
Therefore, the dipsticks also allow semi-quantitative
analysis of artemisinins in the ACTs. The current dip-
sticks had been stored at 4 °C for over 2 months and
under ambient temperature for about 2 weeks. No sig-
nificant reduction in sensitivity was detected. Their shelf
life, especially under tropical climate, needs to be vigor-
ously tested.
Further evaluations and improvements of the dipsticks
are needed. Since different dipsticks are designed for dif-
ferent ACTs, the specificity needs to be marked clearly
on the tests to avoid confusion and misuse, since differ-
ent ACTs are often available in the same regions. The
poor water solubility of artemether makes the use of
≥95 % alcohol necessary. In recognition of the potential
difficulty in obtaining ≥95 % alcohol in endemic settings,
we have tried to produce the artesunate dipsticks with a
lower detection limit (8 μg/ml). Optimization of the dip-
sticks may allow the drugs to be tested at much higher
dilutions directly in water. Further vigorous tests are
needed to determine the stability of the dipsticks under
endemic conditions.
Conclusions
Dipsticks based on specific mAbs against artemisinin
derivatives have been developed as POC assays for
rapid quality control of ACTs in endemic settings.
Field evaluations by different investigators confirmed
the satisfactory performance of and applicability of the
tests to artesunate- and artemether-containing drugs.
Though the results are qualitative and maximally
semi-quantitative, these simple assays are well suited
for a quick screen to identify suspicious fake and sub-
standard artemisinin-containing drugs.
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